Trial Profile

A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TEV 53408 (Primary)
Indications Vitiligo
Focus Adverse reactions; Therapeutic Use
Sponsors Teva Branded Pharmaceutical Products R&D

Most Recent Events

11 Aug 2025 Planned number of patients changed from 28 to 36.
24 Mar 2025 Planned number of patients changed from 24 to 28.
20 Nov 2024 Planned End Date changed from 21 Jun 2027 to 5 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com